Moderna, Inc. to Post FY2022 Earnings of $21.61 Per Share, SVB Leerink Forecasts (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNAGet Rating) – Equities research analysts at SVB Leerink upped their FY2022 earnings per share estimates for Moderna in a report issued on Tuesday, January 17th. SVB Leerink analyst M. Foroohar now anticipates that the company will post earnings of $21.61 per share for the year, up from their prior estimate of $19.43. SVB Leerink has a “Market Perform” rating and a $111.00 price objective on the stock. The consensus estimate for Moderna’s current full-year earnings is $21.16 per share. SVB Leerink also issued estimates for Moderna’s Q4 2022 earnings at $5.14 EPS, Q1 2023 earnings at $2.55 EPS, Q2 2023 earnings at $2.54 EPS, Q4 2023 earnings at $2.51 EPS, FY2023 earnings at $10.13 EPS and FY2024 earnings at $11.01 EPS.

MRNA has been the subject of several other research reports. JPMorgan Chase & Co. cut their price target on Moderna from $165.00 to $122.00 and set a “neutral” rating for the company in a research note on Monday, October 24th. Cowen dropped their price objective on Moderna from $165.00 to $145.00 in a report on Thursday, October 20th. Morgan Stanley upped their price objective on Moderna from $170.00 to $209.00 and gave the stock an “equal weight” rating in a report on Friday, December 16th. Cowen dropped their price objective on Moderna from $165.00 to $145.00 in a report on Thursday, October 20th. Finally, Chardan Capital upped their price objective on Moderna from $191.00 to $208.00 and gave the stock a “neutral” rating in a report on Wednesday. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus price target of $194.00.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $193.98 on Friday. Moderna has a twelve month low of $115.03 and a twelve month high of $217.25. The company has a current ratio of 2.10, a quick ratio of 1.80 and a debt-to-equity ratio of 0.05. The stock has a 50 day moving average of $185.39 and a two-hundred day moving average of $160.91. The stock has a market cap of $74.52 billion, a P/E ratio of 7.02 and a beta of 1.71.

Moderna (NASDAQ:MRNAGet Rating) last issued its quarterly earnings data on Thursday, November 3rd. The company reported $2.53 earnings per share for the quarter, missing analysts’ consensus estimates of $3.04 by ($0.51). Moderna had a net margin of 55.00% and a return on equity of 70.03%. The firm had revenue of $3.36 billion during the quarter, compared to analysts’ expectations of $3.33 billion.

Insider Buying and Selling at Moderna

In related news, Director Noubar Afeyan sold 10,000 shares of the stock in a transaction on Wednesday, January 18th. The stock was sold at an average price of $200.20, for a total transaction of $2,002,000.00. Following the sale, the director now owns 2,247,209 shares of the company’s stock, valued at $449,891,241.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, Director Noubar Afeyan sold 10,000 shares of the stock in a transaction on Wednesday, January 18th. The stock was sold at an average price of $200.20, for a total transaction of $2,002,000.00. Following the sale, the director now owns 2,247,209 shares of the company’s stock, valued at $449,891,241.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction on Wednesday, October 26th. The shares were sold at an average price of $142.51, for a total value of $5,700,400.00. Following the sale, the chief executive officer now directly owns 5,411,946 shares in the company, valued at approximately $771,256,424.46. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 495,899 shares of company stock valued at $87,285,286. Insiders own 17.30% of the company’s stock.

Hedge Funds Weigh In On Moderna

Large investors have recently added to or reduced their stakes in the business. Total Clarity Wealth Management Inc. purchased a new position in Moderna during the second quarter worth about $25,000. FinTrust Capital Advisors LLC raised its holdings in shares of Moderna by 754.5% in the 2nd quarter. FinTrust Capital Advisors LLC now owns 188 shares of the company’s stock worth $31,000 after purchasing an additional 166 shares during the period. Armstrong Advisory Group Inc. purchased a new position in shares of Moderna in the 4th quarter worth about $38,000. Ronald Blue Trust Inc. raised its holdings in shares of Moderna by 307.4% in the 4th quarter. Ronald Blue Trust Inc. now owns 220 shares of the company’s stock worth $26,000 after purchasing an additional 166 shares during the period. Finally, EWG Elevate Inc. purchased a new position in shares of Moderna in the 4th quarter worth about $41,000. 63.11% of the stock is currently owned by hedge funds and other institutional investors.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

Earnings History and Estimates for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.